Assessment of vancomycin utilization among Lebanese hospitals

References

1. ↵
   1. Gupta A,
   2. Biyani M,
   3. Khaira A

   (2011) Vancomycin nephrotoxicity:myths and facts. Neth J Med 69:379–383.

   OpenUrlPubMed
2. 1. Dehority W

   (2010) Use of vancomycin in pediatrics. Pediatr Infect Dis J 29:462–464.

   OpenUrlCrossRefPubMed
3. ↵
   1. Hardman JG,
   2. Limbird LE

   1. Chambers F

   (2010) in Goodman and Gilman's the pharmacological basis of therapeutics, Antimicrobial agents:Protein synthesis inhibitors and miscellaneous antibacterial agents, eds Hardman JG, Limbird LE (McGraw-Hill, New York (NY)), 11th ed, pp 1074–1077.
4. ↵
   1. Hazlewood KA,
   2. Brouse SD,
   3. Pitcher WD,
   4. Hall RG

   (2010) Vancomycin-associated nephrotoxicity:grave concern or death by character assassination? Am J Med 123:182.e1–e7.

   OpenUrlCrossRefPubMed
5. ↵
   1. Hicks RW,
   2. Hernandez J

   (2011) Perioperative pharmacology:a focus on vancomycin. AORN J 93:593–596, quiz 597-599.

   OpenUrlPubMed
6. ↵
   1. Plan O,
   2. Cambonie G,
   3. Barbotte E,
   4. Meyer P,
   5. Devine C,
   6. Milesi C,
   7. et al.

   (2008) Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections:a new dosage schedule. Arch Dis Child Fetal Neonatal Ed 93:F418–F421.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Schilling A,
   2. Neuner E,
   3. Rehm SJ

   (2011) Vancomycin:a 50-something-year-old antibiotic we still don't understand. Cleve Clin J Med 78:465–471.

   OpenUrlAbstract/FREE Full Text
8. ↵
   1. McKinnon PS,
   2. Davis SL

   (2004) Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis 23:271–288.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Rybak M,
   2. Lomaestro B,
   3. Rotschafer JC,
   4. Moellering R Jr.,
   5. Craig W,
   6. Billeter M,
   7. et al.

   (2009) Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98.

   OpenUrlFREE Full Text
10. ↵
    1. Morrison AP,
    2. Melanson SE,
    3. Carty MG,
    4. Bates DW,
    5. Szumita PM,
    6. Tanasijevic MJ

    (2012) What proportion of vancomycin trough levels are drawn too early?frequency and impact on clinical actions. Am J Clin Pathol 137:472–478.

    OpenUrlCrossRefPubMed
11. 1. McCluggage L,
    2. Lee K,
    3. Potter T,
    4. Dugger R,
    5. Pakyz A

    (2010) Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system. Am J Health Syst Pharm 67:70–75.

    OpenUrlAbstract/FREE Full Text
12. ↵
    1. Traugott KA,
    2. Maxwell PR,
    3. Green K,
    4. Frei C,
    5. Lewis JS 2nd.

    (2011) Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm 68:347–352.

    OpenUrlAbstract/FREE Full Text
13. 1. Damfu N,
    2. Aseeri M,
    3. Davis A,
    4. Hasan H,
    5. &Ismail S

    (2016) The Impact of Pharmacist Led Vancomycin Order Set Implementation in a Computerized-Prescriber-Order-Entry (CPOE) System at a Tertiary Care Centre:A Quasi Experimental Study. Journal of Pharmacovigilance, 04.
14. ↵
    1. Bakke V,
    2. Sporsem H,
    3. Von der Lippe E,
    4. Nordøy I,
    5. Lao Y,
    6. Nyrerød HC,
    7. et al.

    (2017) Vancomycin levels are frequently subtherapeutic in critically ill patients:a prospective observational study. Acta Anaesthesiol Scand 61:627–635.

    OpenUrlPubMed
15. ↵
    1. Blot S,
    2. Koulenti D,
    3. Akova M,
    4. Bassetti M,
    5. De Waele JJ,
    6. Dimopoulos G,
    7. et al.

    (2014) Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients?Data from the multinational DALI study. Crit Care 18:R99.

    OpenUrl
16. 1. Ye ZK,
    2. Tang HL,
    3. Zhai SD

    (2013) Benefits of therapeutic drug monitoring of vancomycin:a systematic review and meta-analysis. PLoS One (8):e77169.
17. 1. Al Za'abi M,
    2. Shafiq S,
    3. Al Riyami D,
    4. Ali B

    (2013) Utilization Pattern of Vancomycin in a University Teaching Hospital in Oman:Comparison with International Guidelines. Tropical Journal of Pharmaceutical Research, 12.
18. ↵
    1. Phillips CJ,
    2. Gordon DL

    (2015) Pharmacist-led implementation of a vancomycin guideline across medical and surgical units:impact on clinical behavior and therapeutic drug monitoring outcomes. Integr Pharm Res Pract 4:145–152.

    OpenUrl
19. ↵
    1. Islahudin F,
    2. Ong HY

    (2014) Appropriate vancomycin use in a Malaysian tertiary hospital based on current HICPAC recommendations. J Infect Dev Ctries 8:1267–1271.

    OpenUrl
20. ↵
    1. Moise PA,
    2. Schentag JJ

    (2000) Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 16:S31–S34.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. Rosini JM,
    2. Grovola MR,
    3. Levine BJ,
    4. Jasani NB

    (2013) Prescribing habits of vancomycin in the Emergency Department:are we dosing appropriately? J Emerg Med 44:979–984.

    OpenUrlCrossRefPubMed
22. ↵
    1. Grace E

    (2012) Altered vancomycin pharmacokinetics in obese and morbidly obese patients:what we have learned over the past 30 years. J Antimicrob Chemother 67:1305–1310.

    OpenUrlCrossRefPubMed